Cyanotech Income from Continuous Operations 2010-2025 | CYAN

Cyanotech income from continuous operations from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Cyanotech Income from Continuous Operations 2010-2025 | CYAN

Cyanotech income from continuous operations from 2010 to 2025. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72.3B
Zoetis (ZTS)$69B
Daiichi Sankyo, - (DSNKY)$51.1B
Takeda Pharmaceutical (TAK)$48.4B
BeOne Medicines - (ONC)$34.3B
Sandoz Group AG (SDZNY)$26.7B
Summit Therapeutics (SMMT)$18.8B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$15.1B
United Therapeutics (UTHR)$14.1B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.2B
IPSEN (IPSEY)$11.2B
Eisai (ESAIY)$9.4B
Madrigal Pharmaceuticals (MDGL)$8.4B
Corcept Therapeutics (CORT)$7.4B
Grifols, S.A (GRFS)$7B
Stevanato Group S.p.A (STVN)$6.8B
Ionis Pharmaceuticals (IONS)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Ono Pharmaceutical (OPHLF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
Ocular Therapeutix (OCUL)$2.1B
Endo (NDOI)$1.8B